Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Huntington's Disease Clinical Trials

6 recruiting trials for Huntington's Disease. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
6
Total Trials
6
Recruiting Now
0
Phase 3 Trials
5
Sponsors

Recruiting Trials

RECRUITINGNCT01860339

Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease

Huntington's Disease (HD) is an autosomal dominant disease manifested in a triad of cognitive, psychiatric, and motor signs and symptoms. HD is caused by a triplet repeat...

Sponsor: Peggy C NopoulosEnrolling: 4006 locations
RECRUITINGNCT02855476

HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for...

HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for...

Sponsor: University College, LondonEnrolling: 250020 locations
RECRUITINGPhase 1NCT06585449

A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.

Sponsor: Alnylam PharmaceuticalsEnrolling: 6619 locations
RECRUITINGEarly Phase 1NCT06634628

iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009

This is a FIH (first-in-human) study to evaluate the clinical utility of the radioligand \[11C\]CHDI-00491009 as a PET tracer that binds specifically to mutant huntingtin (mHTT)...

Sponsor: CHDI Foundation, Inc.Enrolling: 271 location
RECRUITINGPhase 1NCT07246941

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease

This is a first-in-human (FIH) study of RG6496 that will assess the safety and tolerability of single-ascending doses of RG6496 administered to huntington's disease gene expansion...

Sponsor: Hoffmann-La RocheEnrolling: 403 locations
RECRUITINGNCT01574053

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and...

Sponsor: CHDI Foundation, Inc.Enrolling: 3500020 locations